Literature DB >> 28248200

The role of the complement system in cancer.

Vahid Afshar-Kharghan.   

Abstract

In addition to being a component of innate immunity and an ancient defense mechanism against invading pathogens, complement activation also participates in the adaptive immune response, inflammation, hemostasis, embryogenesis, and organ repair and development. Activation of the complement system via classical, lectin, or alternative pathways generates anaphylatoxins (C3a and C5a) and membrane attack complex (C5b-9) and opsonizes targeted cells. Complement activation end products and their receptors mediate cell-cell interactions that regulate several biological functions in the extravascular tissue. Signaling of anaphylatoxin receptors or assembly of membrane attack complex promotes cell dedifferentiation, proliferation, and migration in addition to reducing apoptosis. As a result, complement activation in the tumor microenvironment enhances tumor growth and increases metastasis. In this Review, I discuss immune and nonimmune functions of complement proteins and the tumor-promoting effect of complement activation.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28248200      PMCID: PMC5330758          DOI: 10.1172/JCI90962

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  107 in total

1.  Complement resistance of human carcinoma cells depends on membrane regulatory proteins, protein kinases and sialic acid.

Authors:  N Donin; K Jurianz; L Ziporen; S Schultz; M Kirschfink; Z Fishelson
Journal:  Clin Exp Immunol       Date:  2003-02       Impact factor: 4.330

Review 2.  Complement and its role in innate and adaptive immune responses.

Authors:  Jason R Dunkelberger; Wen-Chao Song
Journal:  Cell Res       Date:  2009-12-15       Impact factor: 25.617

3.  Complement Component 3 Is Regulated by TWIST1 and Mediates Epithelial-Mesenchymal Transition.

Authors:  Min Soon Cho; Rajesha Rupaimoole; Hyun-Jin Choi; Kyunghee Noh; Jichao Chen; Qianghua Hu; Anil K Sood; Vahid Afshar-Kharghan
Journal:  J Immunol       Date:  2015-12-30       Impact factor: 5.422

4.  Increased serum levels of complement C3a anaphylatoxin indicate the presence of colorectal tumors.

Authors:  Jens K Habermann; Uwe J Roblick; Brian T Luke; Darue A Prieto; William J J Finlay; Vladimir N Podust; John M Roman; Elisabeth Oevermann; Thomas Schiedeck; Nils Homann; Michael Duchrow; Thomas P Conrads; Timothy D Veenstra; Stanley K Burt; Hans-Peter Bruch; Gert Auer; Thomas Ried
Journal:  Gastroenterology       Date:  2006-10       Impact factor: 22.682

5.  Human colonic epithelial cells detect and respond to C5a via apically expressed C5aR through the ERK pathway.

Authors:  Qi Cao; Shayla M McIsaac; Andrew W Stadnyk
Journal:  Am J Physiol Cell Physiol       Date:  2012-04-11       Impact factor: 4.249

Review 6.  Neutralizing tumor-promoting chronic inflammation: a magic bullet?

Authors:  Lisa M Coussens; Laurence Zitvogel; A Karolina Palucka
Journal:  Science       Date:  2013-01-18       Impact factor: 47.728

7.  Complement activation product C4d in oral and oropharyngeal squamous cell carcinoma.

Authors:  D Ajona; M J Pajares; M D Chiara; J P Rodrigo; E Jantus-Lewintre; C Camps; C Suarez; J V Bagán; L M Montuenga; R Pio
Journal:  Oral Dis       Date:  2015-09-07       Impact factor: 3.511

Review 8.  Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors.

Authors:  Z Fishelson; N Donin; S Zell; S Schultz; M Kirschfink
Journal:  Mol Immunol       Date:  2003-09       Impact factor: 4.407

9.  The Complement C3a Receptor Contributes to Melanoma Tumorigenesis by Inhibiting Neutrophil and CD4+ T Cell Responses.

Authors:  Jamileh A Nabizadeh; Helga D Manthey; Frederik J Steyn; Weiyu Chen; Alexander Widiapradja; Fazrena N Md Akhir; Glen M Boyle; Stephen M Taylor; Trent M Woodruff; Barbara E Rolfe
Journal:  J Immunol       Date:  2016-04-20       Impact factor: 5.422

10.  Cellular and complement-dependent cytotoxicity of Ep-CAM-specific monoclonal antibody MT201 against breast cancer cell lines.

Authors:  N Prang; S Preithner; K Brischwein; P Göster; A Wöppel; J Müller; C Steiger; M Peters; P A Baeuerle; A J da Silva
Journal:  Br J Cancer       Date:  2005-01-31       Impact factor: 7.640

View more
  140 in total

1.  Complement C3a and C5a receptors promote GVHD by suppressing mitophagy in recipient dendritic cells.

Authors:  Hung Nguyen; Sandeepkumar Kuril; David Bastian; Jisun Kim; Mengmeng Zhang; Silvia G Vaena; Mohammed Dany; Min Dai; Jessica Lauren Heinrichs; Anusara Daenthanasanmak; Supinya Iamsawat; Steven Schutt; Jianing Fu; Yongxia Wu; David P Fairlie; Carl Atkinson; Besim Ogretmen; Stephen Tomlinson; Xue-Zhong Yu
Journal:  JCI Insight       Date:  2018-12-20

Review 2.  Immunologic factors involved in the malignant transformation of endometriosis to endometriosis-associated ovarian carcinoma.

Authors:  S Leenen; M Hermens; P J de Vos van Steenwijk; R L M Bekkers; E M G van Esch
Journal:  Cancer Immunol Immunother       Date:  2021-01-07       Impact factor: 6.968

3.  An Unusual Cause of Mosaic Attenuation.

Authors:  Jeremy F Weinberger; Ying-Chun Lo; Sara O Vargas; R Elaine Cagnina
Journal:  Am J Respir Crit Care Med       Date:  2020-07-01       Impact factor: 21.405

Review 4.  Deciphering the Intricate Roles of Radiation Therapy and Complement Activation in Cancer.

Authors:  Jacob Gadwa; Sana D Karam
Journal:  Int J Radiat Oncol Biol Phys       Date:  2020-07-03       Impact factor: 7.038

Review 5.  Clinical relevance of lung-restricted antibodies in lung transplantation.

Authors:  Mahzad Akbarpour; Qiang Wu; Xianpeng Liu; Haiying Sun; Emilia Lecuona; Rade Tomic; Sangeeta Bhorade; Thalachallour Mohanakumar; Ankit Bharat
Journal:  Hum Immunol       Date:  2019-05-08       Impact factor: 2.850

6.  Adipose-derived stem cells enhance human breast cancer growth and cancer stem cell-like properties through adipsin.

Authors:  Hideaki Goto; Yohei Shimono; Yohei Funakoshi; Yoshinori Imamura; Masanori Toyoda; Naomi Kiyota; Seishi Kono; Shintaro Takao; Toru Mukohara; Hironobu Minami
Journal:  Oncogene       Date:  2018-09-03       Impact factor: 9.867

7.  Acute myeloid leukemia and fatal Scedosporium prolificans sepsis after eculizumab treatment for paroxysmal nocturnal hemoglobinuria: a case report.

Authors:  Madhura Hanmantgad; Rajat Nog; Karen Seiter
Journal:  Stem Cell Investig       Date:  2017-12-22

8.  Complement Activation via a C3a Receptor Pathway Alters CD4+ T Lymphocytes and Mediates Lung Cancer Progression.

Authors:  Jeff W Kwak; Jennifer Laskowski; Howard Y Li; Maria V McSharry; Trisha R Sippel; Bonnie L Bullock; Amber M Johnson; Joanna M Poczobutt; Alexander J Neuwelt; Stephen P Malkoski; Mary C Weiser-Evans; John D Lambris; Eric T Clambey; Joshua M Thurman; Raphael A Nemenoff
Journal:  Cancer Res       Date:  2017-11-08       Impact factor: 12.701

9.  Complement as Prognostic Biomarker and Potential Therapeutic Target in Renal Cell Carcinoma.

Authors:  Britney Reese; Ashok Silwal; Elizabeth Daugherity; Michael Daugherity; Mahshid Arabi; Pierce Daly; Yvonne Paterson; Layton Woolford; Alana Christie; Roy Elias; James Brugarolas; Tao Wang; Magdalena Karbowniczek; Maciej M Markiewski
Journal:  J Immunol       Date:  2020-11-06       Impact factor: 5.422

10.  Inhibition of complement C1s in patients with cold agglutinin disease: lessons learned from a named patient program.

Authors:  Georg Gelbenegger; Christian Schoergenhofer; Ulla Derhaschnig; Nina Buchtele; Christian Sillaber; Michael Fillitz; Thomas M Schenk; Shirley D'Sa; Ronwyn Cartwright; James C Gilbert; Bernd Jilma; Ulrich Jaeger
Journal:  Blood Adv       Date:  2020-03-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.